Source-grounded facts extracted from KIORA PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michael Meluzio was appointed as principal financial officer and principal accounting officer at KIORA PHARMACEUTICALS INC.
“the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.”
Sarah Romano resigned as Chief Financial Officer at KIORA PHARMACEUTICALS INC.
“Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022”
Sarah Romano resigned as Chief Financial Officer at KIORA PHARMACEUTICALS INC.
“On February 9, 2022, Sarah Romano, the Chief Financial Officer of Kiora Pharmaceuticals, Inc. (the “Company”), notified the Company that she will resign as Chief Financial Officer effective as of February 25, 2022 (the “Effective Date”) to pursue another opportunity.”
Paul Chaney was appointed as non-executive Chairman at KIORA PHARMACEUTICALS INC.
“the Board appointed Paul Chaney as non-executive Chairman of the Board”
Erin Parsons was appointed as Director at KIORA PHARMACEUTICALS INC.
“On January 31, 2022, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Erin Parsons as a member of the Board.”
Stephen From resigned as Executive Chairman at KIORA PHARMACEUTICALS INC.
“Effective of January 31, 2022, Stephen From voluntarily resigned as Executive Chairman of the Company and as a member of the Board.”
David Hollander was appointed as Director at KIORA PHARMACEUTICALS INC.
“On December 13, 2021, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed David Hollander, MD, MBA as a member of the Board to fill a vacancy created by the previously disclosed resignations of two directors from the Board in August 2021.”
Eric J. Daniels was appointed as Chief Development Officer at KIORA PHARMACEUTICALS INC.
“the Board of Directors (the “Board”) of the Company appointed Eric J. Daniels, MD, MBA as Chief Development Officer of the Company.”
Michael Manzo departed as Vice President of Engineering at KIORA PHARMACEUTICALS INC.
“Effective as of August 20, 2021, Michael Manzo ceased serving as the Vice President of Engineering of EyeGate Pharmaceuticals, Inc.”
Steven Boyd resigned as Director at KIORA PHARMACEUTICALS INC.
“On August 3, 2021, I. Keith Maher, MD and Steven Boyd resigned from the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”), effective immediately.”
I. Keith Maher, MD resigned as Director at KIORA PHARMACEUTICALS INC.
“On August 3, 2021, I. Keith Maher, MD and Steven Boyd resigned from the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”), effective immediately.”
Brian M. Strem was appointed as Class I Director at KIORA PHARMACEUTICALS INC.
“the Board, upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board from seven to eight members, and appointed Dr. Strem as a Class I director to fill the resulting vacancy, in each case effective as of the Effective Date”
Franz Obermayr changed role as EVP Clinical Development at KIORA PHARMACEUTICALS INC.
“Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.”
Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.
“On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President and Chief Executive Officer of the Company, effective as of July 26, 2021 (the “Effective Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.